We have recently reported that cardiac lineage protein-1 (CLP-1), a nuclear protein with an acidic region that constitutes a potential protein-protein interaction domain, regulates transcription of the cardiac myosin light chain-2v (MLC-2v) gene promoter in a manner consistent with its being a transcriptional co-activator or regulator. To test the postulate that CLP-1 is a regulator of cardiac genes we ablated the CLP-1 gene in mice. Past embryonic day (E)16.5, CLP-1 null alleles did not show Mendelian inheritance suggesting that absence of CLP-1 was lethal in late fetal stages. CLP-1 (2 /2 ) fetal hearts exhibited a reduced left ventricular chamber with thickened myocardial walls, features suggestive of cardiac hypertrophy. Electron microscopic analysis of E16.5 CLP-1 (2 /2 ) ventricular myocardium showed a marked decline in cell density and altered nuclear and myofibril morphologies similar to that seen in animal models of hypertrophic heart. Analysis of contractile and non-contractile protein genes known to be re-expressed during cardiac hypertrophy showed them to have higher expression levels in CLP-1 (2/2) hearts thereby confirming the hypertrophic phenotype at the molecular level. Analysis of cardiac development genes showed that expression of the HAND1 transcription factor, a gene involved in patterning of the heart tube and down-regulated in hypertrophic hearts, was also significantly reduced in CLP-1 (2 /2 ) fetal hearts. CLP-1 and HAND1 have similar expression patterns in the developing heart ventricles. These data suggest that CLP-1 and the HAND transcription factors may be part of a genetic program critical to proper heart development, perturbation of which can lead to cardiomyopathy.
Introduction
Heart development involves a complex genetic regulatory program designed to ensure the proper temporal and spatial expression of cardiac transcription factors (Srivastava and Olson, 2000) . Early cardiac transcription factors such as the homeobox Nkx2.5, GATA and MEF2 factors contribute to the formation of the linear heart tube and control the expression of subordinate transcription factors such as HAND1 (eHAND) and HAND2 (dHAND), COUP-TFII, NF-ATc, and Irx4 (Searcy et al., 1998; Lien et al., 1999; Biben and Harvey, 1997) . In addition to this cascade-type of gene control, combinatorial interactions between genes are also evident (Nemer and Nemer, 2001; Sepulveda et al., 2002) . For example, GATA factors can directly interact with the Nkx2.5 transcription factor (Durocher et al., 1997) to activate cardiac-specific genes and Nkx2.5 factors themselves are known to interact with T-box transcription factors to promote cardiomyocyte differentiation (Hiroi et al., 2001) . In addition to combinatorial interactions between transcription factors, transcriptional co-activators also play an important role in the expression of cardiogenic genes. The activity of GATA4 on cardiac gene promoters can be negatively or positively regulated by the zinc-finger protein FOG2 (Lu et al., 1999; Svensson et al., 2000) and positively regulated by the co-activator p300 (Dai and Markham, 2001) . Recent evidence points to yet another level of transcriptional control by a new class of regulatory proteins that control the co-activators themselves. A prototypic example of these proteins is the CITED (C BP/p300-interacting transactivator with ED-rich tail) family of proteins that bind to and regulate the activity of the p300 co-activator (Bhattacharya et al., 1999) .
The extent to which each of these various regulatory proteins controls the expression level of cardiogenic genes and how critical these mechanisms are to the cardiac phenotype can be discerned from gene knockout studies. Ablation of transcription factors such as GATA4 (Molkentin et al., 1997) and Nkx2.5 result in impaired cardiac looping and aborted heart development suggesting an essential role for these 'core' transcription factors in early heart development. Ablation of the GATA4 transcriptional co-activator p300 (Yao et al., 1998) , the repressor/activator FOG2 (Tevosin et al., 2000) , the transcriptional co-repressor HOP (Chen et al., 2002; Shin et al., 2002) , and the CITED2 gene (Bamforth et al., 2001 ) also lead to cardiac defects but at later stages of development and with less severe consequences suggesting that the modulatory role these factors play in transcriptional regulation, while important, is not as critical to the early events of cardiogenesis. While a logical relationship between gene function and knockout phenotype can be subjected to a number of influences (gene redundancy, compensatory function by homologous genes, etc.), it nonetheless appears that for transcriptional proteins, the severity of their knockout phenotype may be determined to some degree by whether they perform an essential or modulatory role in the transcription of target genes.
We have cloned and analyzed the gene that encodes mouse CLP-1, a potential transcriptional co-factor that may regulate the transcription of target genes by interacting with other factors within the transcriptional complex (Huang et al., 2002) . CLP-1 is expressed early in vertebrate development with enriched expression in early cardiac tissues (Ghatpande et al., 1999; Huang et al., 2002) . To further assess the role of CLP-1 in development, we have created CLP-1 knockout mice. We report that the CLP-1 null phenotype is lethal late in gestation. Analysis of CLP-1 (2 /2 ) fetuses prior to their death shows them to have hearts with reduced left ventricular chamber size and thickened myocardial walls, a phenotype indicative of cardiac hypertrophy. In addition, the absence of CLP-1 results in a preferential down-regulation of mRNA for the eHAND gene, a transcription factor implicated in left-heart development. These results provide further evidence for CLP-1 being a transcriptional co-factor important for cardiac development.
Results

2.
1. Genotype analysis of the CLP-1 null mutation shows the absence of CLP-1 to be embryonic lethal Previous studies have suggested a possible role for CLP-1 as a transcriptional regulator that interacts with other protein elements of the transcriptional complex to control MLC-2v gene expression (Huang et al., 2002) . To gain further insight into the role of the CLP-1 protein in development and to provide some indication of its role in the control of cardiac genes in vivo, we sought to construct mice lacking the CLP-1 gene. A CLP-1 gene replacement vector was constructed and used to generate CLP-1 (þ /2 ) embryonic stem cells that were then used to produce CLP-1 (2 /2 ) mice (Fig. 1A) . Southern blot analysis of the ES cell clones showed the presence of a 4.5 kb CLP-1-hybridizing band indicative of site-specific targeting of the CLP-1 gene (Fig. 1B) . These ES cells were used to generate CLP-1 knockout mice and a similar analysis of the offspring of CLP-1 (þ /2 ) matings (E16 through to newborns) showed the presence of a single 4.5 kb band indicating homozygosity for the CLP-1 null allele (Fig. 1C) . Northern blot analysis of CLP-1 expression showed CLP-1 mRNA levels to be reduced in CLP-1 (þ /2 ) mice while CLP-1 mRNA was undetectable in CLP-1 (2 /2 ) mice (Fig. 1D) .
In genotyping the first 10 litters of CLP-1 (þ /2 ) matings, we failed to observe CLP-1 (2 /2 ) offspring suggesting that the absence of the CLP-1 gene was lethal to embryos. To determine if the targeted CLP-1 allele was segregating in a Mendelian fashion and when during development CLP-1 (2 /2 ) embryonic lethality occurs, we genotyped E12.5 through E18.5 embryos and fetuses obtained from CLP-1 (þ /2 ) matings. A representative example of the genotyping for one litter is shown in Fig. 1E . Tabulating the genotypes of viable E15.5 through E18.5 offspring obtained from a number of matings shows that the Mendelian segregation of the CLP-1 allele is maintained until E16.5 (Table 1) . From E17.5 onwards, the frequency of CLP-1 (2 /2 ) viable offspring is significantly below what would be expected from a normal Mendelian inheritance. This suggests that the absence of the CLP-1 gene is lethal to fetuses at this point in their development.
In certain instances, we could isolate litters of CLP-1 (þ /2 ) matings in which CLP-1 (2 /2 ) fetuses had not yet died and undergone resorbtion. Viable CLP-1 (2 /2 ) fetuses from E16.5 through E18.5 were paler and smaller than either wild type or CLP-1 (þ /2 ) fetuses, whereas fetuses from E16 and younger were phenotypically indistinguishable from their normal or heterozygous littermates. Among the possibilities that could explain the discrete onset of this phenotype in late gestation, the pale appearance and reduced size of CLP-1 (2 /2 ) fetuses point to a possible cardiovascular dysfunction. This has been noted in other knockout mice exhibiting a defective cardiovascular system, in which the lack of blood suffusing the developing fetus is thought to lead to necrosis and shrinking of tissues owing to a lack of oxygen transfer and diffusion of bloodborne nutrients (Bamforth et al., 2001; Copp, 1995) .
2.2. Morphological and histological examination of the heart of CLP-1 (2 /2 ) fetuses Given the above observations and the documented expression of CLP-1 in heart-forming and fully formed heart tissue (Ghatpande et al., 1999; Huang et al., 2002) , we focused our initial morphological assessment of the CLP-1 (2 /2 ) phenotype on the hearts of CLP-1 (2 /2 ) fetuses. When compared to normal littermates, gross inspection of the hearts from CLP-1 (2 /2 ) fetuses and newborns showed them to be morphologically altered (On occasion, CLP-1 (2 /2 ) fetuses survived until a few hours after birth allowing study of the newborn CLP-1 (2 /2 ) heart. Interestingly, variable survival rates have been seen in other mice carrying null alleles for transcriptional regulators (Chen et al., 2002; Shin et al., 2002) ). In general, the overall length and width of the hearts appeared different with the CLP-1 (2 /2 ) heart being slightly smaller along the longitudinal axis and wider along the lateral axis ( Fig. 2A, panels a and b ). In addition, there was a slight but reproducible diminution in the size of the left atrium of CLP-1 (2 /2 ) hearts (0.374^0.03 cm 2 ) compared to wild-type hearts (0.536^0.05 cm 2 ) ðP , 0:05Þ as assessed by area measurements of Fig. 2A using NIH Image (version 1.57) software (Division of Computer Research and Technology, National Institutes of Health, Bethesda, MD). The reduced size of CLP-1 (2 /2 ) atria was confirmed in sagittal sections taken from or near the same sectional plane of E17.5 wild type and CLP-1 knockout hearts (Fig. 2B) . To assess CLP-1 (2 /2 ) hearts for other morphological abnormalities, we performed a series of coronal histological sections of hearts isolated from E19.5 fetuses. A total of seven CLP-1 (2 /2 ) fetuses were analyzed with representative sections from an individual wild type and CLP-1 (2 /2 ) fetus shown in Fig. 2C . The most immediately evident alteration is the anomaly in the left ventricular chamber. In all cases, hearts from CLP-1 (2 /2 ) fetuses (panel b) exhibited a smaller left ventricular cavity (0.65^0.009 cm 2 ) than wild-type hearts (panel a; 1.44^0.006 cm 2 ). (All quantitative comparisons are between fetuses taken from the same litter). In addition, CLP-1 (2 /2 ) hearts had thickened left ventricular septal and outer walls (0.374^0.02 cm) compared to that of wild-type hearts (0.29^0.03 cm) ðP , 0:05Þ: From these studies, we conclude that CLP-1 (2 /2 ) fetal hearts exhibit an abnormally thickened left ventricular myocardium with a decrease in size of the left ventricular chamber as well as the left atrium.
To further investigate the aberrant heart morphology seen at the gross level and histological level, we conducted electron microscopic analysis of fetal hearts to assess the integrity of the CLP-1 (2 /2 ) fetal heart myocardium. We selected two embryonic ages for our analysis: E16.5, just prior to the period in which null embryos die, and E15.5, Tail genomic DNA from fetuses taken from a number of litters was genotyped by PCR as detailed in Fig. 1 and the numbers of (þ /þ ), (þ/2), and (2/2) fetuses tabulated. Only those fetuses that overtly appeared viable were genotyped; non-viable embryos that were resorbed were not genotyped because of necrosis. The percentage of viable CLP-1 (2/2) fetuses per the total number of fetuses is listed in the last column. The numbers in parentheses refer to the number of non-viable fetuses in the offspring examined. These were not genotyped due to their resorbtion and necrotic state, but given the observed frequencies of (þ /þ ) and (þ /2) CLP-1 fetuses and assuming a Mendelian inheritance for the CLP-1 null allele, these resorbed fetuses were likely to be CLP-1 (2/2). Embroyos were genotyped by PCR (see Section 4).
a Three embryos were not genotyped due to atrophy/necrosis. b Four embryos were not genotyped due to atrophy/necrosis.
an earlier age to determine if changes are occurring in embryos that are not yet at risk. From light microscopic analysis of myocardium, it was immediately apparent that the myocardium of the E16.5 CLP-1 null fetus contained far fewer cells with more intercellular space than the more cellularized and compact wild type or E15.5 CLP-1 (2 /2 ) myocardiums. Cells appeared smaller and darker with increased uptake of Toluidine stain possibly due to condensation and shrinkage resulting from apoptosis (data not shown). Thin sections analysed by electron microscopy (EM) confirmed this: wild type nuclei showed evenly distributed chromatin and internally located nucleoli characteristic of healthy cells (Fig. 3a ,e), while E16.5 CLP-1 null myocardium showed cell nuclei with electron dense chromatin masses coalesced near to and abutting the nuclear envelope (Fig. 3g ). The E16.5 CLP-1 (2 /2 ) myocardium also exhibited fewer myofibrils (MF) than wild type and of these many did not have detectable Z bands characteristic of well-formed sarcomeres, (compare panels h and f, Fig. 3 ). Mitochondria also appeared compromised: in CLP-1 null myocardium the inner cell membrane structures characteristic of mitochrondria, the cristae, were elaborated to a far less degree than that seen in wild type myocardium (data not shown). Interestingly, compared to Hematoxylin and eosin stained sagittal sections of wild-type (þ /þ ) (a) and CLP-1 (2/2) (b) E17.5 fetal hearts. Abbreviations: LA, left atrium; a, aortic trunk/proximal part of arch of aorta; t, right lobe of thymus gland. Only sections in which the thymus ('t' in (B) was of similar size between wild type and CLP-1 (2/2) mice were used in order to ensure valid size comparisons. The size difference between wild type and CLP-1 (2/2) left atria appears accentuated relative to wild type due to the angle of sectioning. (C) Histological examination of CLP-1 wild type and (2/2) fetal hearts. Hematoxylin and eosin stained coronal sections of E19.5 wild type (a) and CLP-1 (2/2) hearts (b) are shown. Abbreviations: RV, right ventricle; LV, left ventricle. Photomicrographs were subjected to further analysis for size differences using NIH Image 1.57 software.
the myocardium of a wild type littermate (panels a and b), the E15.5 CLP-1 null myocardium (panels c and d) appears virtually normal with respect to nuclear and myofibril morphology suggesting that the demise of the CLP-1 null heart takes place within the narrow developmental window between E15.5 and E16.5. These ultrastructural changes are reminiscent of those seen in the myocardium of hearts from spontaneously hypertensive rats (SHR) and suggest that as with the SHR heart, the hearts of CLP-1 null fetuses may be undergoing apoptosis associated with hypertrophy of the myocardium (Liu et al., 2000) .
Northern blot analysis of hypertrophic marker gene expression in CLP-1 (2 /2 ) fetal hearts
These morphological anomalies of CLP-1 (2 /2 ) fetal hearts detailed above are features typical of cardiac hypertrophy. One hallmark of cardiac hypertrophy is the re-expression of a fetal program of contractile protein genes and non-contractile protein genes such as atrial natriuretic factor (ANF) as part of the adaptive response to hypertrophic stimuli (Schaub et al., 1997; Chien et al., 1991) . We sought to determine if these same genes are expressed at higher levels in CLP-1 (2 /2 ) fetal hearts as part of an adaptive response that would indicate the hypertrophic state. Since the 'normal' fetal program controlling expression of these genes may be active during this same late fetal stage, we were careful to compare levels in CLP-1 (2 /2 ) fetal hearts with those in wild-type and CLP-1 (þ /2 ) littermates. We assessed the expression of three genes known to be up-regulated during cardiac hypertrophy: beta-myosin heavy chain (beta-MHC) (Lompre et al., 1991; Schwartz et al., 1992; Calderone et al., 1995) , ANF (Izumo et al., 1988; Mercadier et al., 1989; Schwartz et al., 1986; Black et al., 1991) , and alphaskeletal actin (Calderone et al., 1995; Izumo et al., 1988; Schwartz et al., 1986; Black et al., 1991) . Northern blot analysis of total RNA from E16 fetal hearts showed reduced levels and complete absence of CLP-1 mRNA in CLP-1 (þ / 2 ) and CLP-1 (2 /2 ) fetal heart, respectively (Fig. 4A) . Parallel northern blots probed for beta-MHC, ANF, and alpha-skeletal actin mRNAs showed increased levels for Fig. 3 . Electron microscopic analysis of the myocardium of E15.5 and E16.5 wild type and CLP-1 null fetal hearts. (A) E15.5 fetal heart myocardium: panels a and b are from wild type fetuses, panels c and d are from CLP-1 (2/2) fetuses. For both wild type and CLP-1 knockout myocardiums, the morphology of the nucleus (N) and MF appears normal. (B) E16.5 fetal heart myocardium: panels e and f are from wild type fetuses, panels g and h are from CLP-1 (2/2) fetuses. Note the abnormal distribution of chromatin and nucleoli within the nucleus (N) of the E16.5 CLP-1 (2/2) myocardium (panel g) versus wild type and E15.5 CLP-1 (2/2) myocardium (panels e and c, respectively). (CC refers to chromatin condensation at the nuclear envelope). The typical Z band patterning of the myofibril sarcomere (denoted by asterisks) was evident in the myofibrils (outlined) of wild type myocardium (panels b and f) and E15.5 CLP-1 (2/2) myocardium (panel d), but was less evident in that of the CLP-1 knockout myocardium (panel h).
these genes in the CLP-1 knockout heart compared to wild type and CLP-1 (þ /2 ) heterozygous hearts (Fig. 4B) . The increased expression of contractile protein genes in CLP-1 (2 /2 ) hearts parallels what is seen in the adaptive response of adult heart to hypertrophic stimuli. Thus, CLP-1 (2 /2 ) fetal hearts exhibit morphological anomalies of the left ventricular chamber and aberrant marker gene expression consistent with that seen in adult cardiac hypertrophy.
RT-PCR analysis of early cardiogenic gene transcripts in wild type and homozygous CLP-1 (2 /2 ) heart tissues
The observations of a structurally altered left ventricular myocardium and expression of genetic markers associated with myocardial hypertrophy in CLP-1 (2 /2 ) fetal hearts indicates that CLP-1 may play a role in the development and function of heart ventricles. Since CLP-1 has been shown to be expressed as early as the pre-cardiac mesoderm (Ghatpande et al., 1999) , its absence could result in aberrant patterning and morphogenesis of the early heart tube that results in altered ventricle formation and function. These events are likely to be controlled by early patterning genes such as homeobox genes or other transcription factors known to partition the developing heart tube into its eventual left and right compartments. To begin to address this, we selected candidate genes within these categories that have been demonstrated to be essential for proper heart morphogenesis: the homeobox gene Nkx2.5 Biben and Harvey, 1997; Durocher et al., 1997; Hiroi et al., 2001) , the transcription factor gene GATA4 (Durocher et al., 1997; Molkentin et al., 1997) , and the HAND genes (Srivastava et al., 1995; Biben and Harvey, 1997; Thomas et al., 1998; Natarajan et al., 2001) which are essential for specifying the ventricular chambers of the heart. We determined expression levels of these genes in hearts isolated just prior to the onset of fetal death in CLP-1 (2 /2 ) fetuses and in early stages of heart development when these genes are most highly expressed. Semiquantitative RT-PCR analysis of mRNA expression levels for these genes in E16.5, E17.5, and E18.5 CLP-1 (2 /2 ) hearts versus wild-type hearts was achieved by quantifying the intensity of RT-PCR/Southern blot bands and normalizing them to a GAPDH control gene (presented as a ratio between test gene and GAPDH levels). All three ages tested gave essentially the same results; the data for E16.5 hearts is presented in Fig. 5 . For dHAND and eHAND genes, a significant decrease in eHAND mRNA levels was evident (approximately 65% less than wild-type levels, p , 0:05), with an insignificant decrease in dHAND mRNA levels ( Fig.  6A and B) . For Nkx2.5 and GATA4, mRNA levels in CLP-1 (2 /2 ) heart tissue were similar to that of wild-type hearts ( Fig. 5C and D) .
Given the demonstrated down-regulation of HAND gene expression in E16.5 hypertrophic heart, we next sought to examine if HAND gene expression is reduced in CLP-1 (2 /2 ) embryonic heart. Previous studies have shown that eHAND expression is highest in the E8.5 mouse heart tube with decreased expression at later stages of development . These observations and the early developmental expression of CLP-1 in heart suggested that peak levels of interaction between these genes and potentially greater differences in the level of HAND gene expression might occur in younger CLP-1 (2 /2 ) hearts. We therefore performed an analysis of HAND gene expression in the heart tubes of E9.5 wild type and CLP-1 (2 /2 ) homozygous knockout embryos. Target mRNAs were amplified using RT-PCR procedures in accord with those of Natarajan et al. (2001) that provide for a linear relation between amplification and product band intensity (see Section 4). Quantitation of CLP-1 RT-PCR products Fig. 4 . Northern blot analysis of wild type, heterozygous, and knockout CLP-1 fetal hearts. E16 fetal heart RNA was isolated from fetuses genotyped for disrupted CLP-1 alleles and subjected to Northern blot analysis. Blots were initially hybridized with a beta-actin probe to establish variability in amounts of loaded RNA. (A) Northern blot analysis of CLP-1 mRNA. CLP-1 coding region probe reveals two bands of appropriate size relative to ribosomal RNA markers (Huang et al., 2002) . (þ /þ ) lane shows CLP-1 mRNA levels in wild type E16 fetal hearts, with reduced levels in CLP-1 (þ /2) hearts and no detectable expression in CLP-1 knockout hearts. (B) Northern blot analysis of contractile protein gene markers for cardiac hypertrophy. Alpha-skeletal actin, Beta-MHC, and ANF mRNAs show detectable increases in CLP-1 (2/2) fetal hearts relative to wild type littermate heart. Slight increases are apparent for alpha-skeletal actin, higher increases for beta-MHC, and substantial increases for ANF (overexposure of ANF blot shows bands in wild type and CLP-1 (þ /2) heterozygote E16 heart in accordance with published observations) (Mercadier et al., 1989; Schwartz et al., 1986; Black et al., 1991). normalized to GAPDH internal controls revealed wild type (high CLP-1 mRNA levels) versus knockout (no CLP-1 mRNA present) heart tubes with intermediate levels representing heterozygous embryos (Fig. 6A ). Of these, two embryos (#'s 2 and 3, wild type and knockout, respectively) were selected for analysis of HAND gene expression. Both eHAND and dHAND expression was found to be decreased approximately 80% in CLP-1 knockout heart tubes relative to wild type heart tubes (Fig. 6B) . These findings suggest that absence of the CLP-1 gene product (see Fig. 4A CLP-1 (2 /2 ) lane) results in decreased expression of the eHAND and dHAND genes. These results together with those of the RT-PCR analysis of E16.5-18.5 hearts suggests that in the absence of the CLP-1 gene product eHAND expression is reduced and continues to be reduced in late fetal hearts exhibiting hypertrophy. On the other hand, dHAND expression is diminished in early heart tube but exhibits near normal expression levels in later stages of the hypertrophic fetal heart.
In situ hybridization analysis of CLP-1 gene expression in early heart tube
Our finding that eHAND mRNA is reduced in CLP-1 knockout fetal heart raises two possibilities, the first being that in normal mouse embryos CLP-1 controls the formation of cells expressing eHAND and the second being that CLP-1 is either directly or indirectly involved in up-regulating eHAND gene expression. To begin to address this, we performed in situ hybridization studies to determine if, at the very least, CLP-1 mRNA is expressed in the same tissues as eHAND. We performed in situ hybridization analyses of E9.5 and E10.5 mouse embryos, the ages most RT-PCR analysis of cardiogenic gene expression in E16.5 wild-type and CLP-1 (2/2) fetal hearts. Fetal hearts were taken from E16.5 littermates from a CLP-1 (2/2) mating and total RNA subjected to RT-PCR amplification followed by Southern blot analysis using gene-specific probes. Mocha quantification software was used to quantitate RT-PCR bands generated from five different wild type and homozygous CLP-1 (2/2) hearts. Expression data is presented as the ratio between test gene levels and control gene (GAPDH) levels. Statistical analysis was performed using ExCell and represented graphically using . Analysis of CLP-1 and HAND gene expression in heart tubes from E9.5 wild type, CLP-1 (þ/2) heterozygous, and CLP-1 (2/2) homozygous knockout embryos. RNA from E9.5 heart tubes of littermates from a CLP-1 heterozygote mating was subjected to RT-PCR analysis using 32 P end-labelled gene-specific primers and gel electrophoresed (both ethidium bromide-stained gels and their autoradiograms are shown). (A) Expression of the GAPDH gene (positive/quantitation control) and the CLP-1 gene. Embryos #'s 1, 2, 5, and 9 showed highest levels of CLP-1 mRNA indicating wild type embryos, with #'s 4, 7, 8, and possibly 6 showing lower levels indicative of heterozyogous embryos. Embryo #3 showed no detectable CLP-1 mRNA indicating the homozygous CLP-1 knockout. Embryos #2 and #3, wild type and homozyogous knockout, respectively, were further analysed for expression of the HAND genes. (B) Expression of the HAND genes. Heart tube RNAs from embryos #2 and #3 were subjected to RT-PCR with primers for eHAND and dHAND mRNAs. Upper panel shows the ethidium bromide stained bands and their corresponding autoradiograms. Lower panel shows the quantitation of these bands by phosphorimage analysis (all data for CLP-1, eHAND, and dHAND PCR products are normalized to those of GAPDH PCR prior to plotting). Both eHAND and dHAND PCR products are decreased by approximately 80% in CLP-1 knockout E9.5 heart tubes. comparable to that of chicken development in which CLP-1 appears to have peak expression levels (Ghatpande et al., 1999) . Whole mount in situ hybridization shows CLP-1 to be widely expressed throughout the E9.5 and E10.5 mouse embryo (Fig. 7a,d ), while eHAND expression is seen to be restricted to the left side of the heart, the branchial arches (BA), and lateral mesoderm (LM) (Fig. 7b ,e,h; Srivastava et al., 1997) . At this level of analysis, dHAND appears to be expressed in the BA and LM with barely detectable levels in the heart (Fig. 7c,f,i,l) . Ventral views of E10.5 embryos show that for CLP-1 and eHAND, expression is predominantly localized to the left side of the heart (outlined) and to the BA (Fig. 7j,k) . These data show that, in general, CLP-1 is expressed in the same areas of the developing heart as eHAND and is also expressed in the BA and LM, as is eHAND and dHAND. In addition, CLP-1 is expressed at low levels throughout other tissues of the embryo.
To ascertain where in the developing heart CLP-1 is expressed relative to the HAND genes, we sectioned embryos subjected to in situ hybridization. Within the E9.5 mouse heart, CLP-1 is expressed in the left ventricular myocardium with expression extending through the atrioventricular canal (AVC) and abruptly ending at the atria (A) (Fig. 8a) . CLP-1 mRNA is also seen in the myocardium of the right ventricle (RV) with expression restricted to the rightward side of the ventricle. eHAND expression is found in the left side of the left ventricle (LV) and common atria of the E9.5 embryo as well as in the right side of the RV (Fig. 8b) . Expression in the RV could be a remnant of the bilateral expression of eHAND seen in younger embryos (Biben and Harvey, 1997) . dHAND expression is low throughout the heart tube with higher expression in the outflow tract and in the mesoderm cranial to the heart (Biben and Harvey, 1997) . In E10.5 embryos, CLP-1 is Fig. 8 ). Higher magnification of the bracketed regions in panels d-f are shown in panels g-i. In addition to heart, branchial arches (BA) and lateral mesoderm (LM) express all three genes. Panels j,k, and l are ventral views of E10.5 embryos hybridized with CLP-1, eHAND, and dHAND antisense riboprobes, respectively. Hearts are outlined by dashed lines for better visualization from this angle. expressed in the leftward side of the myocardium of the LV with faint but detectable expression maintained in the rightward side of the RV myocardium (Fig. 8d) . eHAND expression is seen only in the LV with the strong right ventricular expression seen in E9.5 now barely detectable ( Fig. 8e ; Thomas et al., 1998) . dHAND expression is maintained in the RV; expression is also seen in the atrioventricular canal (AVC) and in the septum primum of the common atrial chamber (Fig. 8f) . In addition to heart expression, CLP-1 is also expressed in various other regions of the developing embryo, particularly those of neural origin (Fig. 8C ). Among these are the dorsal neural tube (panel g), neural crest cells migrating from the dorsal neural tube (panel h), the BA (panel i), the inner neural cell layer of the optic cup (panel k), the dorsal mesentery of the hindgut (panel l), and the inner cell layer of the otic vesicle (panel m) (In chicken, CLP-1 is expressed in the inner ear, specifically the supporting cells of the cochlear; personal communication, Stefan Heller, Harvard University). The HAND genes have also been shown to be expressed in the BA of embryonic mice and chickens (Biben and Harvey, 1997; Srivastava et al., 1995 Srivastava et al., , 1997 . With respect to expression in the developing heart, these results show that CLP-1, despite an overall less-restricted pattern of expression than eHAND in early mouse development, nonetheless, shows colocalized expression with eHAND in the LV of the E9.5 and E10.5 mouse heart.
Discussion
Our findings indicate that the absence of the CLP-1 gene results in a fetal form of cardiac hypertrophy that ultimately leads to fetal or perinatal death. The absence of CLP-1 leads to up-regulation of Beta MHC, alpha-skeletal actin and ANF genes in the fetal heart, a pattern classically associated with the hypertrophic state and part of the adaptive response of the heart to pressure overload. In addition, we have also shown that the expression of two early transcription factors, eHAND and dHAND, is also affected in CLP-1 (2 /2 ) fetal heart: eHAND expression is decreased in both E9.5 and E16 CLP-1 (2 /2 ) heart while dHAND is decreased in E9.5 heart and attains near normal levels in the late fetal stage E16 heart. The HAND transcription factors play a critical role in the patterning of the early heart tube and its segmental specification into regions destined to form the right and left ventricular compartments (Srivastava and Olson, 2000; Thomas et al., 1998; Srivastava, 1999) . dHAND expression is restricted to that region of the heart tube fated to form the future RV while eHAND is expressed in the anterior and posterior segments of the heart tube which go on to form the LV. At the morphological level, the absence of CLP-1 leads to abnormalities in the left atrium and ventricle of the fetal heart, while at the molecular level a significant decrease in eHAND mRNA levels is evident. The decreased expression of eHAND in CLP-1 (2 /2 ) mice is consistent with the proposed function of eHAND in determining right/left symmetry and left ventricular development. Together, these observations suggest that CLP-1 and eHAND are components of the genetic pathway underlying normal LV development. Perturbation of this pathway may lead to aberrant left-hand heart chamber formation that could lead to a form of early onset (i.e. fetal) ventricular cardiac hypertrophy.
Loss of CLP-1 did not result in changes in Nkx2.5 or GATA4 levels in fetal heart. From a developmental viewpoint, this suggests that CLP-1 operates independently of these two transcription factors. In certain but not all types of hypertrophy, Nkx2.5 and GATA4 do not appear to be upregulated, although there are reports that in adrenergicinduced hypertrophy, Nkx2.5 is induced (Saadane et al., 1999) and that GATA4 activation may be critical for modulating cardiac genes under various conditions of hypertrophy (Liang et al., 2002) . In contrast, HAND gene expression is decreased in rat adult heart when hypertrophy is induced either pharmacologically or by pressure overload (Thattaliyath et al., 2002) . Interpreting our results in light of these findings suggests that either CLP-1 is a positive activator of eHAND and that decreased eHAND expression in CLP-1 (2 /2 ) fetuses promotes hypertrophy or that the absence of CLP-1 leads to cardiac hypertrophy, a consequence of which is decreased eHAND expression. Given that we see a decrease in eHAND expression in the E9.5 CLP-1 (2 /2 ) heart tube prior to hypertrophy, we favor the first possibility. While the demonstration of a direct role of eHAND in cardiac hypertrophy has been hampered by the early embryonic lethality of eHAND knockout mice (Firulli et al., 1998; Riley et al., 1998) , the decreased expression of eHAND in CLP-1 (2 /2 ) mice suggests to us that the malfunctioning of the fetal heart late in gestation may have as root cause disrupted expression of early cardiogenic genes and disrupted morphogenesis of the early heart tube.
Our primary goal in ablating the CLP-1 gene was to gather more information on its role as a possible transcription co-factor in cardiac and other tissue-specific gene expression. Comparison of the CLP-1 knockout mouse phenotype with the phenotypes of other knockout mice is informative in this regard. Disruption of Irx4, a cardiacspecific homeobox gene expressed in the ventricular myocardium, leads to aberrant ventricular gene expression and left ventricular hypertrophy at 24 weeks of age (Bruneau et al., 2001) . As with the CLP-1 knockout, Irx4 knockout mice showed diminished eHAND mRNA expression and abnormal thickening of the myocardial walls of the LV. Echocardiographic analysis of Irx4 (2 /2 ) mice indicated cardiomyopathy involving myocardial hypertrophy, chamber dilation, and systolic dysfunction. While a similar analysis of CLP-1 (2 /2 ) fetuses is not feasible, our analysis of contractile protein gene expression showed patterns very similar to that of Irx4 (2 /2 ) mice (see Fig. 2 ; Bruneau et al., 2001 ). This pattern is most similar to that seen in pressure overload hypertrophy versus hypertrophy induced by cytokines or growth factors (Schaub et al., 1997; Schwartz et al., 1986 Schwartz et al., , 1992 Calderone et al., 1995; Izumo et al., 1988; Mercadier et al., 1989; Black et al., 1991) .
While the phenotypic similarity to Irx4 (2 /2 ) mice is noteworthy, differences exist that might shed some light on the etiology of CLP-1 (2 /2 ) fetal death. The most evident is that death occurs prenatally rather than postnatally as with the Irx4 knockout mice. This suggests that whatever is structurally aberrant with CLP-1 hearts, it is manifest functionally during late fetal stages. One possibility is that a structurally compromised CLP-1 (2 /2 ) fetal heart may try but fail to meet the hemodynamic demands of a rapidly expanding fetal circulatory system resulting in cardiac dysfunction and death. The most overt structural anomaly of CLP-1 (2 /2 ) hearts is a thickened left ventricular wall and reduced left ventricular chamber size. Because these are observations of hearts from live fetuses (dead fetuses being resorbed), we cannot say for sure if these hearts had or had not been subject to pressure overload. This leaves open the possibility that the observed thickened myocardium existed prior to any pressure overload suggesting that abnormal growth processes may be responsible. One piece of evidence that suggests otherwise is our recent finding that CLP-1 (þ /2 ) heterozygotes, which live to adulthood, nonetheless show a pronounced and rapid onset of cardiac hypertrophy when subjected to trans-aortic constriction (unpublished observations). We are presently studying the structure of the pre-constricted myocardium of these mice to determine what subtle changes, if any, lead to this enhanced response to hypertrophic stimuli.
While our evidence points to aberrant heart development and cardiac hypertrophy as the most likely cause of death in CLP-1 (2 /2 ) fetuses, the widespread expression pattern of CLP-1 in numerous tissues leaves open the possibility of a non-cardiac etiology. We are presently constructing cre-lox mice with a conditional CLP-1 knockout allele directed solely to cardiomyocytes to address this question more precisely and also to determine when during heart development CLP-1 expression is required. Finally, it is interesting to note that despite CLP-1's role as a potential regulator of cardiac transcription, heart development is not aborted in knockout fetuses but rather progresses to yield a fully formed yet malfunctioning heart. If CLP-1 is critical early in heart development as our studies imply, this would suggest that slight alterations in the cardiogenic program early on, while tolerated for much of heart organogenesis, nonetheless may manifest as lethal liabilities the moment the heart must meet hemodynamic demand. The CLP-1 knockout along with the knockout phenotypes of other cardiac transcriptional regulators support this notion and suggest that the precise control of their target genes is critical to both adult heart formation and function. The availability of large scale screening procedures such as gene microarray analyses should be useful in identifying these target genes and their requisite expression levels in both normal and pathological states not only for CLP-1, but for other regulatory genes implicated in cardiomyopathies. 
Generation of chimeric mice and germ-line transmission of the CLP-1 mutant allele
Cells from the three CLP-1 (þ /2 ) ES cell clones were injected into 3.5-day-old C57BL/6 mouse blastocysts and surgically placed into the uterus of pseudopregnant CD1 female mice and allowed to develop to term. The resulting chimeras were mated to Black Swiss mice to generate agouti animals which were then bred to give mice heterozygous for the targeted CLP-1 allele as determined by polymerase chain reaction (PCR) analysis. CLP-1 primers were as follows: forward primer 5 0 -AACCTCCTCTCCTTGCG-CACCAACTC-3 0 and reverse primer 5 0 -TACTGTCC-TCCTTGGGCACCCGTTCC-3 0 . Neomycin resistance gene primers were: forward primer 5 0 -AACCTCCTCTC-CTTGCGCACCAACTC-3 0 and reverse primer 5 0 -TACC-GGTGGATGTGGAATGTGTGCGA-3 0 . Samples were amplified for 30 cycles (denaturation: 30 s at 94 8C, annealing: 30 s at 68 8C, and elongation: 1 min at 72 8C).
4.3. Preparation of slides and histological analysis of embryos and electron microscopy E17.5 or E18.5 mouse fetuses from heterozygote matings were dissected in PBS and fixed in 10% paraformaldehyde overnight at 4 8C Fixed fetuses were decalcified for 2 days in the cold, washed with distilled water for 2 h, and then processed for paraffin wax tissue sectioning and hematoxylin -eosin histological staining. Some fixed fetuses were sent to the Mutant Mouse HistoPathology Laboratories at the University of California, Davis for analysis. For EM, hearts were fixed in 4% glutarldehyde, imbedded in epon, and sectioned for staining with toulidine blue (10 mm thick) and for EM analysis (1 mm thick).
RT-PCR analysis of E9.5 embryonic heart tubes
Total RNA from E9.5 mouse embryo heart tubes (9 embryos from a mating of CLP-1 (þ /2 ) mice) was isolated using Trizol (Gibco-BRL) and CLP-1, GAPDH, eHAND, and dHAND mRNAs amplified by RT-PCR using radiolabelled gene-specific primers (CLP-1 forward and reverse primers (same as those used in ES cell genotyping; GAPDHforward:GAGCGAGACCCCACTAACATCAAA; GAPDH reverse: GAGGGGCCATCCACAGTCTTCT; eHAND forward: GGGGCCCGGCGAGAAGAGGATTA; eHAND reverse: CGCAGAGCCAAGAAGGGGACGAGA; dHAND forward: GGGCGGTGCTAATTGGGCTGACA; dHAND reverse: GCTTGCTTTCGCGACCAC CATCC. Cycle number was kept to a minimum (18 cycles for E16.5 heart, 30 cycles for E9.5 heart tube RNAs) and radiolabelled amplification products quantified by PhosphoImage Analysis (Molecular Dynamics PhosphoImager and ImageQuant software).
RT-PCR analysis of E16-E18 fetal hearts
Total RNA from fetal hearts was converted to cDNA using AMV reverse transcriptase (Life Technologies, Inc.) and amplification of specific cDNA sequences carried out using PCR methodology. Specific primers used: Nkx2. 30 s at 94 8C, annealing and elongation: 1.5 min at 68 8C) and the amplified products analyzed by Southern blot. Southern blot autoradiograms were scanned and digitized for subsequent quantification of RT-PCR bands using Mocha quantification software. RT-PCR bands generated from five different isolated wild-type and homozygous CLP-1 (2 /2 ) hearts (from E16.5, E17.5, and E18.5 fetuses) were analysed. Statistical analysis was performed using Microsoft Excel and represented graphically using Sigma Plot 4.17 software.
Northern blot analyses of CLP-1 and hypertrophic marker genes
Total RNA was isolated from the livers of E16 CLP-1 fetuses that were genotyped using primers described above for ES cell screening. Twenty micrograms of total RNA were loaded per lane. CLP-1 mRNA was detected using the pFHC17 cDNA insert. To assess variance in loaded RNA amounts, we probed the blots with a mouse beta-actin probe. For analysis of gene markers for cardiac hypertrophy in E16 wild-type, (þ /2 ), and (2 /2 ) CLP-1 fetal hearts, total RNA was isolated from the heart and approximately 9 mm loaded per lane. All hybridization probes are mouse in origin; the ANF probe was generated by PCR amplification, the alpha-skeletal actin probe was provided by Dr L. Kedes (University of Southern Califormia).
In situ hybridizations
Whole mount in situ hybridizations were performed on mouse embryos using standard procedures (Neito et al., 1996; Schweitzer et al., 2001 ) with the following modifications: Proteinase K digestion of embryos was performed for longer times, e.g. overnight at 10 8C, to ensure tissue permeability (as judged by an overall 'flaccidness' in the embryos), and the initial temperature of probe hybridization was kept overnight at between 70 and 75 8C before dropping to temperatures compatible with probe Tm in order to ensure probe infiltration into tissues. Embryos intentionally overstained for sectioning were dehydrated/destained in an increasing methanol series, rehydrated, fixed in 4% paraformaldehyde and paraffin-embedded according to the procedures of Neito et al. (1996) . Ten micrometer-thick sections were taken, mounted, and deparaffinized before photography on a Zeiss AxioSkop using differential interference contrast optics. All images were captured using a digital camera and Axiovision 3.1 software (Carl Zeiss Inc.). eHAND and dHAND antisense and sense riboprobes were generated from plasmid DNAs kindly provided by Dr Eric Olson (University of Texas Southwestern Medical Center). and euthanasia procedures as set forth by the IRB of SUNY Health Science Center at Brooklyn. This work was supported by NIH grants HL53573 and AR41923 from the National Institutes of Health to M.A.Q. Siddiqui.
